CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 108 enrolled
Drug / intervention
Slendertone Facedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01030380
NCT01030380Phase 3Completed
CompareCT.gov

Determination of the Efficacy of Slendertone® Face to Tone the Muscles of the Face and Reduce the Signs of Facial Aging

Bio-Medical Research, Ltd.·interventional·Posted Dec 11, 2009·Updated Dec 11, 2009

In Brief

A Phase 3 clinical trial evaluating Slendertone Face for Facial Muscle Toning. Completed, enrolled 108 participants across 1 site.

Detailed Summary

The purpose of this study was to determine the efficacy of Slendertone® Face™, to tone the muscles of the face and reduce the signs of facial aging among the following characteristics: radiance, tone, lift, firmness and complexion, following a 12-week programme of facial muscle toning. Slendertone® Face is a neuromuscular electrical stimulation (NMES) device which features a headset unit designed for application to the face for facial toning. The purpose of the headset is to locate and support a pair of stimulation electrodes on each side of the face, over the facial nerve just anterior to the ear.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFacial Muscle Toning
CountriesIreland
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 11, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.6 years ago

Interventions

Slendertone Facedevice

Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.